Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Unquoted Biotechs -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (18)	9/25/2001 2:07:27 PM
From: keokalani'nui	Read Replies (1) \| Respond to of 253

>>One to watch<< Definitely. From its web-site: >>Proteomics offers a potentially powerful approach to identify specific tumor antigens and define targets for the development of immunotherapeutics. The limitation of this approach has been the difficulty in developing a quantitative method for the separation of complex mixtures of proteins that can yield specific differences between populations. To define surface expressed proteins that are preferentially expressed on tumor cells, founder Ruedi Aebersold has perfected a method based on the development of an isotope coded affinity tag (ICAT) and tandem mass spectrometry. The relative quantitation is highly accurate because it is based on stable isotope dilution techniques. The system currently deployed is based on the ICAT reagent. The method is based on two principles: 1. A short sequence of contiguous amino acids contains enough information to identify a unique protein and 2. Pairs of peptides tagged with light and heavy ICAT reagents that are chemically identical yet permitting their independent identification by mass spectrometry. The technology is widely applicable to a variety of tissue samples, cell lines or pathological material. Since proteolysis is performed, the constraints of having viable and metabolically active samples are obviated. When combined with the genomic approaches outlined above, the proteomic information offers a powerful integration for identification of target molecules on tumor cells.<< Timely too given RA's recent comments: Message 16408553 It is noteworthy that the ultimate focus is on creating proprietary antibody-based therapeutics. Previous Hood et al incubations have generally stayed true to processes and instrumentation (well, maybe Darwin was an exception). Ditto the 'Thanks Nigel.' Wilder